Study Phase 3

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/​or Transgender Individuals (MOSAICO)

Trial Information

Generic NameAd26.Mos4.HIV and Clade C gp140Product NameN/ATherapeutic AreaAnti-Infectives for Systemic UseProduct ClassVaccinesPharmacological SubgroupViral VaccinesChemical SubgroupOther Viral VaccinesCondition StudiedHIV Infections
Sponsor Protocol NumberVAC89220HPX3002Enrollment3900Data PartnerJohnson & Johnson% Female0.4%Mean/Median Age (Years)29.8% White44.5%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.